Global Acute Respiratory Distress Syndrome Ards Treatment Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2024 –2030 |
 Taille du marché (année de référence) |
|
 Taille du marché (année de prévision) |
Dollars américains 9,954,720.47 |
 TCAC |
% |
| Principaux acteurs du marché |
Marché mondial du traitement du syndrome de détresse respiratoire aiguë (SDRA), par type (ventilation mécanique, corticostéroïdes, médicaments antiviraux, oxygénation extracorporelle par membrane (ECMO), tocilizumab et autres), cause (septicémie, inhalation de substances nocives, pneumonie sévère et autres), voie d'administration (orale, parentérale et autres), utilisateur final (hôpitaux, cliniques spécialisées, soins à domicile et autres), canal de distribution (appel d'offres direct, pharmacie hospitalière, pharmacie de détail et pharmacie en ligne) - Tendances et prévisions du secteur jusqu'en 2030.
Analyse et taille du marché du traitement du syndrome de détresse respiratoire aiguë (SDRA)
La prévalence croissante des maladies infectieuses et respiratoires telles que le syndrome de détresse respiratoire aiguë et l'attention portée au développement de vaccins et de produits thérapeutiques et diagnostiques pour ces pathologies ont accru la demande du marché. Les progrès technologiques pour un approvisionnement facile des produits et des installations de fabrication rapides contribuent également à la croissance du marché. Les principaux acteurs du marché sont très concentrés sur les lancements de produits et les produits.
Data Bridge Market Research estime que le marché mondial du traitement du syndrome de détresse respiratoire aiguë (SDRA) devrait atteindre 9 954 720,47 milliers de dollars d'ici 2030, à un TCAC de 10,6 % au cours de la période de prévision 2023-2030. Ce rapport de marché couvre également en profondeur l'analyse des prix et les avancées technologiques.
|
Rapport métrique |
Détails |
|
Période de prévision |
2023 à 2030 |
|
Année de base |
2022 |
|
Années historiques |
2021 (personnalisable de 2015 à 2020) |
|
Unités quantitatives |
Chiffre d'affaires en milliers de dollars américains, volumes en unités, prix en dollars américains |
|
Segments couverts |
Type (ventilation mécanique, corticostéroïdes, médicaments antiviraux, oxygénation extracorporelle par membrane (ECMO), tocilizumab et autres), cause ( septicémie , inhalation de substances nocives, pneumonie grave et autres), voie d'administration (orale, parentérale et autres), utilisateur final (hôpitaux, cliniques spécialisées, soins à domicile et autres), canal de distribution (appel d'offres direct, pharmacie hospitalière, pharmacie de détail et pharmacie en ligne) |
|
Pays couverts |
États-Unis, Canada, Mexique, Allemagne, France, Royaume-Uni, Italie, Espagne, Russie, Turquie, Belgique, Pays-Bas, Suisse, Reste de l'Europe, Japon, Chine, Corée du Sud, Inde, Australie, Singapour, Thaïlande, Malaisie, Indonésie, Philippines, Reste de l'Asie-Pacifique, Brésil, Argentine, Reste de l'Amérique du Sud, Afrique du Sud, Arabie saoudite, Émirats arabes unis, Égypte, Koweït, Israël et Reste du Moyen-Orient et de l'Afrique |
|
Acteurs du marché couverts |
Gilead Sciences, Inc., Terumo Medical Corporation, Getting, LivaNova PLC. Medtronic, ResMed, Fisher & Paykel Healthcare Limited, Drägerwerk AG & Co. KGaA, NIPRO, Fresenius SE & Co. KGaA, Hamilton Medical, Pfizer Inc., WEINMANN Emergency Medical Technology GmbH + Co. KG, EUROSETS, Armstrong Medical, nice Neotech Medical Systems Pvt. Ltd. et Besmed Health Business Corp., entre autres |
Définition du marché du traitement du syndrome de détresse respiratoire aiguë (SDRA)
Acute respiratory distress syndrome (ARDS) is a life-threatening lung injury that allows fluid to leak into the lungs. Most people who get ARDS are hospitalized for trauma or illness such as COVID-19. The syndrome usually occurs when fluids build up in the tiny, elastic air sacs called alveoli in the lungs. This fluid build-up causes less oxygen to reach the bloodstream. This deprives the organs of getting enough oxygen for their normal function. People with other illness develops ARDS within a few hours to days after the precipitating injury or infection. The risk of death increases with age, and surviving the syndrome becomes hard depending on the severity of the illness.
Acute Respiratory Distress Syndrome (ARDS) Treatment Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Driver
Increasing Prevalence and Incidence of Acute Lung Injury
Patients with acute lung injuries are being widely reported due to numerous factors, such as the increasing aged population and the rising number of patients with sepsis and pneumonia, among others. However, most people get diagnosed with lung injuries and acute respiratory distress syndrome only at the late stages. The disease is a rapidly progressive condition occurring in patients with damaged lungs, causing bodily fluids to leak.
The number of acute respiratory distress syndrome cases and lung injuries is increasing due to the emergence of various respiratory illness-causing viruses in recent years.
The number of prevalent people drinking is also high, further increasing the disorder's burden. Hence, increasing alcohol consumption, irrespective of age, leads to symptoms such as ARDS. Other risk factors, such as dyspnoea, hypertension, diabetes, and more, lead to ARDS development. This wide range of risk factors associated with acute respiratory distress syndrome increases the possibility of developing the clinical condition, simultaneously raising the cases of the disease. These affirmative risk factors are expected to drive market growth.
Opportunity
Rising Healthcare Expenditure to Improve Treatment Facilities
Healthcare expenditure has increased worldwide as disposable income has increased among various countries' populations. Moreover, to accomplish the population requirements, government bodies, and healthcare organizations are taking the initiative by accelerating healthcare expenditure. The rise in healthcare expenditure simultaneously helps healthcare settings to improve their treatment facilities for acute respiratory distress syndrome, as the disorder has been highly prevalent in recent years.
Growing healthcare expenditure is also beneficial for further economic growth and healthcare sector growth, and it is primarily fruitful as it significantly affects the development of better and more advanced therapeutic options with ventilators and other ARDS treatment devices. Thereby, a surge in healthcare expenditure is expected to create opportunities for market growth.
Restraint / Challenge
High Cost of Devices and Treatment
The utilization of critical care and intensive care unit services is increasing worldwide, and its expensive cost is a major concern in the current healthcare system. However, acute respiratory distress syndrome is getting a wide range of advanced treatment options, and the cost of treatment for a long duration is quite difficult for average-income people to afford. Patients with ARDS commonly require long hospitalizations with frequent monetarization and ventilation usage, consuming significant healthcare resources. As a result, most patients who cannot afford a long-term stay get discharged in the initial stages of treatment. However, this increases the possibilities and susceptibilities for new infection complications, which demands additional healthcare resources and treatment.
Recent Developments
- In July 2023, ResMed announced the acquisition of privately held Somnoware, a U.S. leader in sleep and respiratory care diagnostics software. This acquisition helps the organization develop more revenue.
- In October 2022, NIPRO announced that one of its consolidated subsidiaries, Nipro Asia Pte. Ltd., had established a medical device sales subsidiary—Nipro Medical Philippines Corp., in the Republic of the Philippines. This helped the organization develop more revenue.
- In November 2021, Fisher & Paykel Healthcare Limited announced the launch of F&P Visairo Hospital under-nose mask for noninvasive ventilation. F&P Visairo is a new high-performance under-nose hospital mask with dynamic support technology. This allows for bridge-free, noninvasive ventilation, which eliminates pressure from the bridge of the nose and clears the way for an open field of vision without compromising on stability and performance. This helped the company to expand its product portfolio.
- In April 2021, Hamilton Medical announced that they had launched new HAMILTON-C1/T1/MR1 ventilators with various features, including CPR ventilation, upgraded high-flow oxygen therapy, volume Support mode, and digital solutions for respiratory care. This helped the company to increase its global presence in the market and raise their revenues.
- In February 2021, Pfizer CentreOne announced the new campaign of API & Intermediates. This campaign focused on a comprehensive range of complex API compounds and intermediates for drug product developers and manufacturers. This campaign launch helped the company to reach the market.
Acute Respiratory Distress Syndrome (ARDS) Treatment Market Scope
Le marché mondial du traitement du syndrome de détresse respiratoire aiguë (SDRA) est segmenté en cinq segments en fonction du type, de la cause, de la voie d'administration, de l'utilisateur final et du canal de distribution. La croissance de ces segments vous aidera à analyser les segments de croissance limités dans les industries et à fournir aux utilisateurs un aperçu précieux du marché et des informations sur le marché pour les aider à prendre des décisions stratégiques pour identifier les principales applications du marché.
Taper
- Ventilation mécanique
- Corticostéroïdes
- Médicaments antiviraux
- Oxygénation extracorporelle par membrane (ECMO)
- Tocilizumab
- Autres
Sur la base du type, le marché est segmenté en ventilation mécanique, corticostéroïdes, médicaments antiviraux, oxygénation par membrane extracorporelle (ECMO), tocilizumab et autres.
Cause
- État septique
- Inhalation de substances nocives
- Pneumonie grave
- Autres
Sur la base de la cause, le marché est segmenté en septicémie, inhalation de substances nocives, pneumonie grave et autres.
Voie d'administration
- Oral
- Parental
- Autres
Sur la base de la voie d’administration, le marché est segmenté en voie orale , parentérale et autres.
Utilisateur final
- Hôpitaux
- Soins à domicile
- Cliniques spécialisées
- Autres
Sur la base de l’utilisateur final, le marché est segmenté en hôpitaux, cliniques spécialisées, soins de santé à domicile et autres.
Canal de distribution
- Appel d'offres direct
- Pharmacie de l'hôpital
- Pharmacie en ligne
- Pharmacie de détail
Sur la base du canal de distribution, le marché est segmenté en appel d'offres direct, pharmacie hospitalière, pharmacie de détail et pharmacie en ligne .
Analyse/perspectives régionales : marché du traitement du syndrome de détresse respiratoire aiguë (SDRA)
Le marché mondial du traitement du syndrome de détresse respiratoire aiguë (SDRA) est analysé et des informations et tendances sur la taille du marché sont fournies par pays, type, cause, voie d’administration, utilisateur final et canal de distribution, comme référencé ci-dessus.
Les pays couverts dans ce rapport sur le marché mondial du traitement du syndrome de détresse respiratoire aiguë (SDRA) sont les États-Unis, le Canada, le Mexique, l'Allemagne, la France, le Royaume-Uni, l'Italie, l'Espagne, la Russie, la Turquie, la Belgique, les Pays-Bas, la Suisse, le reste de l'Europe, le Japon, la Chine, la Corée du Sud, l'Inde, l'Australie, Singapour, la Thaïlande, la Malaisie, l'Indonésie, les Philippines, le reste de l'Asie-Pacifique, le Brésil, l'Argentine, le reste de l'Amérique du Sud, l'Afrique du Sud, l'Arabie saoudite, les Émirats arabes unis, l'Égypte, le Koweït, Israël et le reste du Moyen-Orient et de l'Afrique.
Les États-Unis devraient dominer la région Amérique du Nord avec la plus grande part de marché en raison de la sensibilisation et du dépistage croissants et de l'augmentation des dépenses de santé. L'Allemagne devrait dominer la région Europe en raison de la prévalence croissante du syndrome de détresse respiratoire aiguë et de la pénétration de nouvelles avancées technologiques. Le Japon devrait dominer la région Asie-Pacifique en raison de l'augmentation des activités de R&D et de la tendance des patients à privilégier les traitements personnalisés.
La section par pays du rapport fournit également des facteurs individuels ayant un impact sur le marché et des changements dans la réglementation du marché qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques, l'analyse des cinq forces de Porter et les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte lors de l'analyse prévisionnelle des données nationales.
Analyse du paysage concurrentiel et des parts de marché du traitement du syndrome de détresse respiratoire aiguë (SDRA)
Le paysage concurrentiel du marché mondial du traitement du syndrome de détresse respiratoire aiguë (SDRA) fournit des détails sur le concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises par rapport au marché.
Français Certains des principaux acteurs du marché opérant sur le marché mondial du traitement du syndrome de détresse respiratoire aiguë (SDRA) sont Gilead Sciences, Inc., Terumo Medical Corporation, Getting, LivaNova PLC. Medtronic, ResMed, Fisher & Paykel Healthcare Limited, Drägerwerk AG & Co. KGaA, NIPRO, Fresenius SE & Co. KGaA, Hamilton Medical, Pfizer Inc., WEINMANN Emergency Medical Technology GmbH + Co. KG, EUROSETS, Armstrong Medical, nice Neotech Medical Systems Pvt. Ltd., et Besmed Health Business Corp., entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 INSURANCE REIMBURSEMENT
4.3.1 CENTER FOR MEDICARE SERVICES (CMS)–ELSO (EXTRACORPOREAL LIFE SUPPORT ORGANIZATION)
4.3.2 HEALTH RESOURCES AND SERVICES ADMINISTRATION
4.3.3 ABBOTT CODING GUIDE FOR ECMO
4.3.4 CENTRAL GOVERNMENT HEALTH SCHEME (CGHS)
4.3.5 CERN HEALTH INSURANCE SCHEME
4.3.6 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) – (MEDICARE & MEDICAID)
4.3.7 AMERICAN HOSPITAL ASSOCIATION
4.4 PIPELINE ANALYSIS
4.5 PRICING ANALYSIS
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY
5.1.2 WIDE RANGE OF RISK FACTORS FOR ARDS TREATMENT
5.1.3 RISING RATE OF AIR POLLUTION AND UNHEALTHY LIFESTYLE
5.1.4 INCREASING ACCIDENT RATES AND TRAUMA CAUSING ARDS
5.2 RESTRAINTS
5.2.1 COMPLICATIONS ASSOCIATED WITH THE TREATMENT
5.2.2 HIGH COST OF DEVICES AND TREATMENT
5.3 OPPORTUNITIES
5.3.1 RISING HEALTHCARE EXPENDITURE TO IMPROVE TREATMENT FACILITIES
5.3.2 STRATEGIC INITIATIVES JOINED WITH NEW PRODUCT LAUNCH BY MARKET PLAYERS
5.3.3 IMPROVING AWARENESS REGARDING ARD SYNDROME
5.4 CHALLENGES
5.4.1 STRINGENT RULES & REGULATIONS
5.4.2 MULTIPLE CHALLENGES FACED BY ICU STAFF
6 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE
6.1 OVERVIEW
6.2 MECHANICAL VENTILATION
6.2.1 HIGH-FLOW NASAL O2
6.2.2 BI-LEVEL POSITIVE AIRWAY PRESSURE
6.2.3 CONTINUOUS POSITIVE AIRWAY PRESSURE
6.2.4 PRONE POSITION VENTILATION
6.2.5 OTHERS
6.3 CORTICOSTEROIDS
6.3.1 METHYLPREDNISOLONE
6.3.2 DEXAMETHASONE
6.3.3 OTHERS
6.4 ANTIVIRAL MEDICATION
6.4.1 RIBAVIRIN
6.4.2 OSELTAMIVIR
6.4.3 OTHERS
6.5 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)
6.6 TOCILIZUMAB
6.7 OTHERS
7 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE
7.1 OVERVIEW
7.2 SEPSIS
7.3 INHALATION OF HARMFUL SUBSTANCES
7.4 SEVERE PNEUMONIA
7.5 OTHERS
8 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
8.1 OVERVIEW
8.2 PARENTERAL
8.2.1 INTRAVENOUS
8.2.2 INTRAMUSCULAR
8.3 ORAL
8.4 OTHERS
9 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.3 SPECIALTY CLINICS
9.4 HOME HEALTHCARE
9.5 OTHERS
10 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 DIRECT TENDER
10.3 HOSPITAL PHARMACY
10.4 RETAIL PHARMACY
10.5 ONLINE PHARMACY
11 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION
11.1 OVERVIEW
11.2 NORTH AMERICA
11.2.1 U.S.
11.2.2 CANADA
11.2.3 MEXICO
11.3 EUROPE
11.3.1 GERMANY
11.3.2 FRANCE
11.3.3 U.K.
11.3.4 ITALY
11.3.5 SPAIN
11.3.6 TURKEY
11.3.7 NETHERLANDS
11.3.8 SWITZERLAND
11.3.9 BELGIUM
11.3.10 RUSSIA
11.3.11 REST OF EUROPE
11.4 ASIA-PACIFIC
11.4.1 JAPAN
11.4.2 CHINA
11.4.3 INDIA
11.4.4 SOUTH KOREA
11.4.5 AUSTRALIA
11.4.6 SINGAPORE
11.4.7 THAILAND
11.4.8 MALAYSIA
11.4.9 INDONESIA
11.4.10 PHILIPPINES
11.4.11 REST OF ASIA-PACIFIC
11.5 SOUTH AMERICA
11.5.1 BRAZIL
11.5.2 ARGENTINA
11.5.3 REST OF SOUTH AMERICA
11.6 MIDDLE EAST AND AFRICA
11.6.1 SOUTH AFRICA
11.6.2 SAUDI ARABIA
11.6.3 U.A.E
11.6.4 ISRAEL
11.6.5 EGYPT
11.6.6 KUWAIT
11.6.7 REST OF MIDDLE EAST AND AFRICA
12 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: GLOBAL
12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
12.3 COMPANY SHARE ANALYSIS: EUROPE
12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
13 SWOT ANALYSIS
14 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT, CPS
14.1 GILEAD SCIENCES INC.
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENT
14.2 TERUMO CORPORATION
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENT
14.3 GETINGE
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENT
14.4 LIVANOVA PLC
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENTS
14.5 MEDTRONIC
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENTS
14.6 ARMSTRONG MEDICAL
14.6.1 COMPANY SNAPSHOT
14.6.2 PRODUCT PORTFOLIO
14.6.3 RECENT DEVELOPMENT
14.7 BESMED HEALTH BUSINESS CORP.
14.7.1 COMPANY SNAPSHOT
14.7.2 PRODUCT PORTFOLIO
14.7.3 RECENT DEVELOPMENTS
14.8 DRÄGERWERK AG & CO. KGAA
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
14.8.4 RECENT DEVELOPMENTS
14.9 EUROSETS
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENT
14.1 FISHER & PAYKEL HEALTHCARE LIMITED
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENTS
14.11 FRESENIUS SE & CO. KGAA.
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENT
14.12 HAMILTON MEDICAL
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENT
14.13 NICE NEOTECH MEDICAL SYSTEMS PVT.LTD.
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 NIPRO
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUE ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENT
14.15 PFIZER INC.
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENT
14.16 RESMED
14.16.1 COMPANY SNAPSHOT
14.16.2 REVENUE ANALYSIS
14.16.3 PRODUCT PORTFOLIO
14.16.4 RECENT DEVELOPMENT
14.17 WEINMANN EMERGENCY MEDICAL TECHNOLOGY GMBH + CO. KG
14.17.1 COMPANY SNAPSHOT
14.17.2 PRODUCT PORTFOLIO
14.17.3 RECENT DEVELOPMENT
15 QUESTIONNAIRE
16 RELATED REPORTS
Liste des tableaux
TABLE 1 LIST OF PRICES FOR APPROVED DRUGS FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT
TABLE 2 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 3 GLOBAL MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 4 GLOBAL MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 5 GLOBAL MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 6 GLOBAL MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 7 GLOBAL CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 8 GLOBAL CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 9 GLOBAL CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 10 GLOBAL CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 11 GLOBAL ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 12 GLOBAL ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 13 GLOBAL ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 14 GLOBAL ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 15 GLOBAL EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 16 GLOBAL TOCILIZUMAB IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 17 GLOBAL OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 18 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)
TABLE 19 GLOBAL SEPSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 20 GLOBAL INHALATION OF HARMFUL SUBSTANCES IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 21 GLOBAL SEVERE PNEUMONIA IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 22 GLOBAL OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 23 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 24 GLOBAL PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 25 GLOBAL PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 26 GLOBAL ORAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 27 GLOBAL OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 28 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 29 GLOBAL HOSPITALS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 30 GLOBAL SPECIALTY CLINICS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 31 GLOBAL HOME HEALTHCARE IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 32 GLOBAL OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 33 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 34 GLOBAL DIRECT TENDER IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 35 GLOBAL HOSPITAL PHARMACY IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 36 GLOBAL RETAIL PHARMACY IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 37 GLOBAL ONLINE PHARMACY IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 38 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 39 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 40 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 41 NORTH AMERICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 42 NORTH AMERICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 43 NORTH AMERICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 44 NORTH AMERICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 45 NORTH AMERICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 46 NORTH AMERICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 47 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)
TABLE 48 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 49 NORTH AMERICA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 50 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 51 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 52 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 53 U.S. MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 54 U.S. MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 55 U.S. MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 56 U.S. CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 57 U.S. CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 58 U.S. CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 59 U.S. ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 60 U.S. ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 61 U.S. ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 62 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)
TABLE 63 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 64 U.S. PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 65 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 66 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 67 CANADA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 68 CANADA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 69 CANADA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 70 CANADA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 71 CANADA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 72 CANADA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 73 CANADA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 74 CANADA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 75 CANADA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 76 CANADA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 77 CANADA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)
TABLE 78 CANADA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 79 CANADA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 80 CANADA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 81 CANADA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 82 MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 83 MEXICO MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 84 MEXICO MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 85 MEXICO MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 86 MEXICO CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 87 MEXICO CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 88 MEXICO CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 89 MEXICO ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 90 MEXICO ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 91 MEXICO ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 92 MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)
TABLE 93 MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 94 MEXICO PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 95 MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 96 MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 97 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 98 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 99 EUROPE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 100 EUROPE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 101 EUROPE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 102 EUROPE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 103 EUROPE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 104 EUROPE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 105 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)
TABLE 106 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 107 EUROPE PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 108 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 109 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 110 GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 111 GERMANY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 112 GERMANY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 113 GERMANY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 114 GERMANY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 115 GERMANY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 116 GERMANY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 117 GERMANY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 118 GERMANY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 119 GERMANY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 120 GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)
TABLE 121 GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 122 GERMANY PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 123 GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 124 GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 125 FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 126 FRANCE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 127 FRANCE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 128 FRANCE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 129 FRANCE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 130 FRANCE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 131 FRANCE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 132 FRANCE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 133 FRANCE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 134 FRANCE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 135 FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)
TABLE 136 FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 137 FRANCE PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 138 FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 139 FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 140 U.K. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 141 U.K. MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 142 U.K. MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 143 U.K. MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 144 U.K. CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 145 U.K. CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 146 U.K. CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 147 U.K. ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 148 U.K. ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 149 U.K. ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 150 U.K. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)
TABLE 151 U.K. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 152 U.K. PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 153 U.K. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 154 U.K. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 155 ITALY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 156 ITALY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 157 ITALY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 158 ITALY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 159 ITALY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 160 ITALY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 161 ITALY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 162 ITALY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 163 ITALY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 164 ITALY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 165 ITALY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)
TABLE 166 ITALY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 167 ITALY PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 168 ITALY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 169 ITALY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 170 SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 171 SPAIN MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 172 SPAIN MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 173 SPAIN MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 174 SPAIN CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 175 SPAIN CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 176 SPAIN CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 177 SPAIN ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 178 SPAIN ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 179 SPAIN ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 180 SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)
TABLE 181 SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 182 SPAIN PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 183 SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 184 SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 185 TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 186 TURKEY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 187 TURKEY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 188 TURKEY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 189 TURKEY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 190 TURKEY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 191 TURKEY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 192 TURKEY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 193 TURKEY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 194 TURKEY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 195 TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)
TABLE 196 TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 197 TURKEY PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 198 TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 199 TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 200 NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 201 NETHERLANDS MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 202 NETHERLANDS MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 203 NETHERLANDS MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 204 NETHERLANDS CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 205 NETHERLANDS CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 206 NETHERLANDS CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 207 NETHERLANDS ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 208 NETHERLANDS ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 209 NETHERLANDS ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 210 NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)
TABLE 211 NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 212 NETHERLANDS PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 213 NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 214 NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 215 SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 216 SWITZERLAND MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 217 SWITZERLAND MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 218 SWITZERLAND MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 219 SWITZERLAND CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 220 SWITZERLAND CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 221 SWITZERLAND CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 222 SWITZERLAND ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 223 SWITZERLAND ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 224 SWITZERLAND ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 225 SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)
TABLE 226 SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 227 SWITZERLAND PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 228 SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 229 SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 230 BELGIUM ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 231 BELGIUM MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 232 BELGIUM MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 233 BELGIUM MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 234 BELGIUM CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 235 BELGIUM CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 236 BELGIUM CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 237 BELGIUM ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 238 BELGIUM ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 239 BELGIUM ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 240 BELGIUM ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)
TABLE 241 BELGIUM ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 242 BELGIUM PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 243 BELGIUM ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 244 BELGIUM ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 245 RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 246 RUSSIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 247 RUSSIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 248 RUSSIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 249 RUSSIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 250 RUSSIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 251 RUSSIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 252 RUSSIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 253 RUSSIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 254 RUSSIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 255 RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)
TABLE 256 RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 257 RUSSIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 258 RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 259 RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 260 REST OF EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 261 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 262 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 263 ASIA-PACIFIC MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 264 ASIA-PACIFIC MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 265 ASIA-PACIFIC CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 266 ASIA-PACIFIC CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 267 ASIA-PACIFIC ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 268 ASIA-PACIFIC ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 269 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)
TABLE 270 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 271 ASIA-PACIFIC PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 272 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 273 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 274 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 275 JAPAN MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 276 JAPAN MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 277 JAPAN MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 278 JAPAN CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 279 JAPAN CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 280 JAPAN CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 281 JAPAN ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 282 JAPAN ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 283 JAPAN ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 284 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)
TABLE 285 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 286 JAPAN PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 287 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 288 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 289 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 290 CHINA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 291 CHINA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 292 CHINA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 293 CHINA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 294 CHINA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 295 CHINA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 296 CHINA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 297 CHINA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 298 CHINA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 299 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)
TABLE 300 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 301 CHINA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 302 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 303 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 304 INDIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 305 INDIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 306 INDIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 307 INDIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 308 INDIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 309 INDIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 310 INDIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 311 INDIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 312 INDIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 313 INDIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 314 INDIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)
TABLE 315 INDIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 316 INDIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 317 INDIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 318 INDIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 319 SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 320 SOUTH KOREA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 321 SOUTH KOREA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 322 SOUTH KOREA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 323 SOUTH KOREA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 324 SOUTH KOREA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 325 SOUTH KOREA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 326 SOUTH KOREA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 327 SOUTH KOREA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 328 SOUTH KOREA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 329 SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)
TABLE 330 SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 331 SOUTH KOREA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 332 SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 333 SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 334 AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 335 AUSTRALIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 336 AUSTRALIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 337 AUSTRALIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 338 AUSTRALIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 339 AUSTRALIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 340 AUSTRALIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 341 AUSTRALIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 342 AUSTRALIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 343 AUSTRALIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 344 AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)
TABLE 345 AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 346 AUSTRALIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 347 AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 348 AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 349 SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 350 SINGAPORE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 351 SINGAPORE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 352 SINGAPORE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 353 SINGAPORE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 354 SINGAPORE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 355 SINGAPORE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 356 SINGAPORE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 357 SINGAPORE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 358 SINGAPORE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 359 SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)
TABLE 360 SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 361 SINGAPORE PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 362 SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 363 SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 364 THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 365 THAILAND MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 366 THAILAND MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 367 THAILAND MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 368 THAILAND CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 369 THAILAND CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 370 THAILAND CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 371 THAILAND ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 372 THAILAND ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 373 THAILAND ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 374 THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)
TABLE 375 THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 376 THAILAND PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 377 THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 378 THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 379 MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 380 MALAYSIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 381 MALAYSIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 382 MALAYSIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 383 MALAYSIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 384 MALAYSIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 385 MALAYSIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 386 MALAYSIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 387 MALAYSIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 388 MALAYSIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 389 MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)
TABLE 390 MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 391 MALAYSIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 392 MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 393 MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 394 INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 395 INDONESIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 396 INDONESIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 397 INDONESIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 398 INDONESIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 399 INDONESIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 400 INDONESIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 401 INDONESIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 402 INDONESIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 403 INDONESIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 404 INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)
TABLE 405 INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 406 INDONESIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 407 INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 408 INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 409 PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 410 PHILIPPINES MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 411 PHILIPPINES MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 412 PHILIPPINES MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 413 PHILIPPINES CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 414 PHILIPPINES CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 415 PHILIPPINES CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 416 PHILIPPINES ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 417 PHILIPPINES ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 418 PHILIPPINES ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 419 PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)
TABLE 420 PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 421 PHILIPPINES PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 422 PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 423 PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 424 REST OF ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 425 SOUTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 426 SOUTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 427 SOUTH AMERICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 428 SOUTH AMERICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 429 SOUTH AMERICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 430 SOUTH AMERICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 431 SOUTH AMERICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 432 SOUTH AMERICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 433 SOUTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)
TABLE 434 SOUTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 435 SOUTH AMERICA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 436 SOUTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 437 SOUTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 438 BRAZIL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 439 BRAZIL MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 440 BRAZIL MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 441 BRAZIL MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 442 BRAZIL CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 443 BRAZIL CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 444 BRAZIL CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 445 BRAZIL ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 446 BRAZIL ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 447 BRAZIL ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 448 BRAZIL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)
TABLE 449 BRAZIL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 450 BRAZIL PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 451 BRAZIL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 452 BRAZIL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 453 ARGENTINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 454 ARGENTINA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 455 ARGENTINA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 456 ARGENTINA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 457 ARGENTINA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 458 ARGENTINA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 459 ARGENTINA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 460 ARGENTINA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 461 ARGENTINA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 462 ARGENTINA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 463 ARGENTINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)
TABLE 464 ARGENTINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 465 ARGENTINA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 466 ARGENTINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 467 ARGENTINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 468 REST OF SOUTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 469 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 470 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 471 MIDDLE EAST AND AFRICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 472 MIDDLE EAST AND AFRICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 473 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 474 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 475 MIDDLE EAST AND AFRICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 476 MIDDLE EAST AND AFRICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 477 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)
TABLE 478 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 479 MIDDLE EAST AND AFRICA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 480 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 481 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 482 SOUTH AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 483 SOUTH AFRICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 484 SOUTH AFRICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 485 SOUTH AFRICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 486 SOUTH AFRICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 487 SOUTH AFRICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 488 SOUTH AFRICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 489 SOUTH AFRICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 490 SOUTH AFRICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 491 SOUTH AFRICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 492 SOUTH AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)
TABLE 493 SOUTH AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 494 SOUTH AFRICA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 495 SOUTH AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 496 SOUTH AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 497 SAUDI ARABIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 498 SAUDI ARABIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 499 SAUDI ARABIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 500 SAUDI ARABIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 501 SAUDI ARABIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 502 SAUDI ARABIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 503 SAUDI ARABIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 504 SAUDI ARABIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 505 SAUDI ARABIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 506 SAUDI ARABIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 507 SAUDI ARABIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)
TABLE 508 SAUDI ARABIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 509 SAUDI ARABIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 510 SAUDI ARABIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 511 SAUDI ARABIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 512 U.A.E ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 513 U.A.E MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 514 U.A.E MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 515 U.A.E MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 516 U.A.E CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 517 U.A.E CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 518 U.A.E CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 519 U.A.E ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 520 U.A.E ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 521 U.A.E ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 522 U.A.E ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)
TABLE 523 U.A.E ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 524 U.A.E PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 525 U.A.E ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 526 U.A.E ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 527 ISRAEL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 528 ISRAEL MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 529 ISRAEL MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 530 ISRAEL MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 531 ISRAEL CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 532 ISRAEL CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 533 ISRAEL CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 534 ISRAEL ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 535 ISRAEL ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 536 ISRAEL ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 537 ISRAEL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)
TABLE 538 ISRAEL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 539 ISRAEL PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 540 ISRAEL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 541 ISRAEL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 542 EGYPT ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 543 EGYPT MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 544 EGYPT MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 545 EGYPT MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 546 EGYPT CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 547 EGYPT CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 548 EGYPT CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 549 EGYPT ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 550 EGYPT ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 551 EGYPT ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 552 EGYPT ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)
TABLE 553 EGYPT ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 554 EGYPT PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 555 EGYPT ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 556 EGYPT ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 557 KUWAIT ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 558 KUWAIT MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 559 KUWAIT MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 560 KUWAIT MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 561 KUWAIT CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 562 KUWAIT CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 563 KUWAIT CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 564 KUWAIT ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 565 KUWAIT ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)
TABLE 566 KUWAIT ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 567 KUWAIT ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)
TABLE 568 KUWAIT ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 569 KUWAIT PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 570 KUWAIT ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 571 KUWAIT ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 572 REST OF MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
Liste des figures
FIGURE 1 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: SEGMENTATION
FIGURE 2 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DBMR MARKET POSITION GRID
FIGURE 8 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: SEGMENTATION
FIGURE 11 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY ARE EXPECTED TO DRIVE THE GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET IN THE FORECAST PERIOD OF 2022 TO 2030
FIGURE 12 MECHANICAL VENTILATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET
FIGURE 14 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY TYPE, 2022
FIGURE 15 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY TYPE, 2023-2030 (USD THOUSAND)
FIGURE 16 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY TYPE, CAGR (2023-2030)
FIGURE 17 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 18 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY CAUSE, 2022
FIGURE 19 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY CAUSE, 2023-2030 (USD THOUSAND)
FIGURE 20 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY CAUSE, CAGR (2023-2030)
FIGURE 21 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY CAUSE, LIFELINE CURVE
FIGURE 22 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022
FIGURE 23 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD THOUSAND)
FIGURE 24 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)
FIGURE 25 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 26 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY END USER, 2022
FIGURE 27 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY END USER, 2023-2030 (USD THOUSAND)
FIGURE 28 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY END USER, CAGR (2023-2030)
FIGURE 29 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 31 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)
FIGURE 32 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 33 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 34 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: SNAPSHOT (2022)
FIGURE 35 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: COMPANY SHARE 2022 (%)
FIGURE 36 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: COMPANY SHARE 2022 (%)
FIGURE 37 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: COMPANY SHARE 2022 (%)
FIGURE 38 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: COMPANY SHARE 2022 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
